Letter: New Thresholds Need to Be Defined When Using Point of Care Assays to Monitor Infliximab Trough Levels in IBD Patients

Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14645
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-Making for IBD Outpatients on Maintenance Infliximab Therapy

Inflammatory Bowel Diseases
AllergyImmunologyGastroenterology
2015English

Letter: Immunogenicity of Infliximab Originator vs. CT-P13 in IBD Patients-Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2014English

What Patients Need to Know About Living With IBD

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

What Patients Need to Know About Living With IBD

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2019English

Higher Infliximab Trough Levels Are Associated With Perianal Fistula Healing in Patients With Crohn's Disease

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Monitor and Control Upstream Bioprocessing Using a Point-Of-Need Mass Spectrometer

Biophysical Journal
Biophysics
2018English

Letter to the Editor. Pupillometry and Neurotrauma: Point-Of-Care Technologies Versus Point-Of-Care Techniques

Journal of Neurosurgery
SurgeryNeurology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy